Lively Q4 ?7 Aug 2018 15:55
On 2 February 2018, N4 Pharma announced that it had been awarded a feasibility grant from Innovate UK to co-fund a collaboration with MedImmune UK, a leading global biologics R&D company, to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec® system. The collaboration has begun well and the Nuvec® team (the "Team") is making significant progress developing manufacturing methods for Nuvec® particles loaded with therapeutic DNA/RNA encoding protein antigens. Once completed, MedImmune will then conduct studies to demonstrate the capability of delivering such antigens to induce immune responses, the results of which are expected in Q4 2018.
Given all of the above, and news on the way forward/or not with Sildenafil due around the end of August we could turn a corner very quickly with so few shares in issue and many in sticky mitts.
A positive way forward on Sild, Positive Medimmune updates and bang where off to the races.
Breach the yearly high for Crimble ? it is not a fantasy on a decent update or 2.
jmo